Regulatory and Industry Requirements for Botanical Drug Products Prof. Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics KLE University College of Pharmacy BELGAUM – 590010, Karnataka, India Cell No: 00919742431000 E-mail: [email protected]01/01/2011 1 BIRDEM & ANRAP, Dhaka, Bangladesh
37
Embed
Regulatory and Industry Requirements for Botanical Drug Products Prof. Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics KLE University.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Regulatory and Industry Requirements for Botanical
Drug Products
Prof. Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D
Department of PharmaceuticsKLE University College of PharmacyBELGAUM – 590010, Karnataka, India
• Although modern medicine is well developed in most of the world, large sections of the population in developing countries still rely on the traditional practitioners, medicinal plants and herbal medicines for their primary care.
• Moreover during the past decades, public interest in natural therapies has increased greatly in industrialized countries, with expanding use of medicinal plants and herbal medicines.
01/01/2011 2BIRDEM & ANRAP, Dhaka, Bangladesh
Traditional Herbal Medicines and Human Health
• Herbal medicines which formed the basis of health care throughout the world since the earliest days of mankind are still widely used, and have considerable importance in international trade.
• Recognition of their clinical, pharmaceutical and economic value is still growing, although this varies widely between countries.
01/01/2011 3BIRDEM & ANRAP, Dhaka, Bangladesh
• There are different ways in which countries define medicinal plants or herbs or products derived from them, and countries have adopted various approaches to licensing, dispensing, manufacturing and trading to ensure their safety, quality and efficacy
Traditional Herbal Medicines and Human Health
01/01/2011 4BIRDEM & ANRAP, Dhaka, Bangladesh
• Despite the use of herbal medicines over many centuries, only a relatively small number of plant species has been studied for possible medical applications.
• Safety and efficacy data are available for an even smaller number of plants, their extracts and active ingredients and preparations containing them.
Traditional Herbal Medicines and Human Health
01/01/2011 5BIRDEM & ANRAP, Dhaka, Bangladesh
Regulation and Registration of Herbal Medicines
• The legal situation regarding herbal preparations varies from country to country.
• Developing countries, however, often have a great number of traditionally used herbal medicines and much folk-knowledge about them.
01/01/2011 6BIRDEM & ANRAP, Dhaka, Bangladesh
GENERAL REGULATORY APPROACHES
• Many botanical products are used widely in the United States. Depending on its labeling and intended use, a botanical product can be a food, a dietary supplement, and/or a drug.
01/01/2011 7BIRDEM & ANRAP, Dhaka, Bangladesh
• Botanicals used for food and consumed primarily for their taste, aroma, or nutritive value are regulated as foods.
• Botanicals can also be dietary supplements if they are labeled as dietary supplements and otherwise meet the dietary supplement definition.
GENERAL REGULATORY APPROACHES
01/01/2011 8BIRDEM & ANRAP, Dhaka, Bangladesh
GENERAL REGULATORY APPROACHES
• If a botanical product is intended to affect the structure or function of the body but does not meet the definition of a dietary supplement, or does not meet the requirements for making a structure/function.
01/01/2011 9BIRDEM & ANRAP, Dhaka, Bangladesh
GENERAL REGULATORY APPROACHES
• As noted above, a botanical product is subject to regulation as a drug under section 201(g)(1)(B) of the Act if it is intended for use in diagnosing, mitigating, treating, curing, or preventing disease.
01/01/2011 10BIRDEM & ANRAP, Dhaka, Bangladesh
GENERAL REGULATORY APPROACHES
• Under section 505(b) of the Act, a drug must be marketed under an approved NDA unless the product is excluded from the definition of a new drug.
• Certain products that FDA determines are generally recognized as safe and effective in accordance.
01/01/2011 11BIRDEM & ANRAP, Dhaka, Bangladesh
Marketing Under OTC Drug Monograph Versus Approved NDA
• A botanical drug product may be marketed in the United States under (1) an OTC drug monograph or (2) an approved NDA or ANDA.
• A botanical product that has been marketed in the United States for a material time and to a material extent for a specific OTC drug indication may be eligible for inclusion in an OTC drug monograph.
01/01/2011 12BIRDEM & ANRAP, Dhaka, Bangladesh
• When a final OTC drug monograph is published for a specific use of a botanical drug, any person may market a product containing the same substance and for the same use, provided the labeling and other active ingredients (if present) are in accord with all relevant monographs and other applicable regulations.
Marketing Under OTC Drug Monograph Versus Approved NDA
01/01/2011 13BIRDEM & ANRAP, Dhaka, Bangladesh
• In contrast, when a product is approved under an NDA, the approval is specific to the drug product that is the subject of the application.
• Mrketing exclusivity for either 5 years (if it is a new chemical entity) or 3 years from the time of approval, even in the absence of patent protection.
Marketing Under OTC Drug Monograph Versus Approved NDA
01/01/2011 14BIRDEM & ANRAP, Dhaka, Bangladesh
CMC Information for Botanical Drug Products
• Because of the complex nature of a typical botanical drug and the lack of knowledge of its active constituent's.
• FDA may rely on a combination of tests and controls to ensure the
- identity, purity, quality, strength, potency, and consistency of botanical drugs.
01/01/2011 15BIRDEM & ANRAP, Dhaka, Bangladesh
CMC Information for Botanical Drug Products
• These tests and controls include
1) Multiple tests for drug substance and drug product (e.g., spectroscopic and/or chromatographic fingerprints, chemical assay of characteristic markers, and biological assay),
2) Raw material and process controls (e.g., strict quality controls for the botanical raw materials and adequate in-process controls), and
3) Process validation (especially for the drug substance).
01/01/2011 16BIRDEM & ANRAP, Dhaka, Bangladesh
CMC and Toxicology Information to Support Initial Studies
• Many botanical products are legally available in the United States as dietary supplements.
• Given the wide availability of such products outside of clinical trials, it is important to assess the effectiveness of such products.
01/01/2011 17BIRDEM & ANRAP, Dhaka, Bangladesh
• To support initial clinical trials, the nonclinical pharmacology and toxicology information that must be provided for legally available botanical products with no known safety issues.
• In most cases, additional toxicology and CMC data will not be required for such initial trials.
CMC and Toxicology Information to Support Initial Studies
01/01/2011 18BIRDEM & ANRAP, Dhaka, Bangladesh
Applicability of Combination Drug Regulations
• Botanical drug products that are derived from a single part of a plant (e.g., leaves, stems, roots, or seeds), or from a single species of alga or macroscopic fungus (e.g., a mushroom), are not considered to be fixed-combination drugs.
01/01/2011 19BIRDEM & ANRAP, Dhaka, Bangladesh
• Consequently, they do not have to meet the requirements for combination drugs, principally the need to demonstrate that each component or active ingredient makes a contribution to claimed effects.
Applicability of Combination Drug Regulations
01/01/2011 20BIRDEM & ANRAP, Dhaka, Bangladesh
MARKETING A BOTANICAL DRUG UNDER AN OTC DRUG MONOGRAPH
• A botanical product that has been marketed in the United States for a material time and to a material extent for a specific OTC indication may be eligible for consideration in the OTC drug monograph system.
• Currently, there are several botanical drugs, including cascara, psyllium, and senna, that are included in the OTC drug review.
01/01/2011 21BIRDEM & ANRAP, Dhaka, Bangladesh
• For a botanical drug substance to be included in an OTC drug monograph, there must be published data establishing general recognition of safety and effectiveness, usually including results of adequate and well-controlled clinical studies.
• Requirements related to safety, effectiveness, and labeling for drugs to be included in an OTC drug monograph.
MARKETING A BOTANICAL DRUG UNDER AN OTC DRUG MONOGRAPH
01/01/2011 22BIRDEM & ANRAP, Dhaka, Bangladesh
MARKETING A BOTANICAL DRUG UNDER AN NDA
• A botanical drug product that is not generally recognized as safe and effective for its therapeutic claims is considered a new drug.
01/01/2011 23BIRDEM & ANRAP, Dhaka, Bangladesh
• NDA must contain substantial evidence of effectiveness derived from adequate and well-controlled clinical studies, evidence of safety, and adequate CMC information.
• The format of an NDA submission and the requirements for its various sections are discussed in several CDER guidance documents.
MARKETING A BOTANICAL DRUG UNDER AN NDA
01/01/2011 24BIRDEM & ANRAP, Dhaka, Bangladesh
INDs FOR BOTANICAL DRUGS
A. IND Information for Different Categories of Botanicals
B. Basic Format for INDs1. Cover Sheet
2. Table of Contents
3. Introductory Statement and General Investigational Plan
4. Investigator’s Brochure
5. Protocols
6. Chemistry, Manufacturing and Controls (CMC)
7. Pharmacology and Toxicology Information
8. Previous Human Experience With the Product
01/01/2011 25BIRDEM & ANRAP, Dhaka, Bangladesh
INDs FOR PHASE 1 AND PHASE 2 CLINICAL STUDIES OF LAWFULLY MARKETED BOTANICAL PRODUCTS WITHOUT SAFETY CONCERNS
A. Description of Product and Documentation of Human Use
1. Description of Botanical Used
2. History of Use
3. Current Marketed Use
B. Chemistry, Manufacturing and Controls1. Botanical Raw Material
2. Botanical Drug Substance
3. Botanical Drug Product
4. Animal Safety
5. Placebo
6. Labeling
7. Environmental Assessment or Claim of Categorical Exclusion01/01/2011 26BIRDEM & ANRAP, Dhaka,
Bangladesh
C. Pharmacology/Toxicology Information1. All Marketed Botanical Products
2. Foreign-Marketed Botanical Products
D. Bioavailability
E. Clinical Considerations
INDs FOR PHASE 1 AND PHASE 2 CLINICAL STUDIES OF LAWFULLY MARKETED BOTANICAL PRODUCTS WITHOUT SAFETY CONCERNS
01/01/2011 27BIRDEM & ANRAP, Dhaka, Bangladesh
INDs FOR PHASE 1 AND PHASE 2 CLINICAL STUDIES FOR NONMARKETED BOTANICAL PRODUCTS AND PRODUCTS WITH KNOWN SAFETY CONCERNS
A. Description of Product and Documentation of Human Use
1. Description of Botanical Used
2. History of Use
3. Current Investigational Use
B. Chemistry, Manufacturing and Control1. Botanical Raw Material
2. Botanical Drug Substance
3. Botanical Drug Product
4. Placebo
5. Labeling
6. Environmental Assessment or Claim of Categorical Exclusion01/01/2011 28BIRDEM & ANRAP, Dhaka,
Bangladesh
C. Nonclinical safety Assessment 1. Traditional Preparations
2. Others
3. Products with Known Safety Issues
D. Bioavailability
E. Clinical Considerations
INDS FOR PHASE 1 AND PHASE 2 CLINICAL STUDIES FOR NONMARKETED BOTANICAL PRODUCTS AND PRODUCTS WITH KNOWN SAFETY CONCERNS
01/01/2011 29BIRDEM & ANRAP, Dhaka, Bangladesh
INDs FOR PHASE 3 CLINICAL STUDIES OF ALL BOTANICAL PRODUCTS
A. Description of Product and Documentation of Human Experience
B. Chemistry, Manufacturing and Control1. Expanded Clinical Studiesa. Botanical raw material
b. Botanical drug substance
c. Botanical drug product
2. End-of-Phase 3 Clinical Studies and Pre-NDA Considerations
01/01/2011 30BIRDEM & ANRAP, Dhaka, Bangladesh
C. Nonclinical Safety Assessment1. Repeat-Dose General Toxicity Studies